Risk factor
Negligible price volatility
Profitability factor
Excellent dividends
About
Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Its offerings also extend to primary care medical services, featuring general practice clinics, occupational health, specialized skin cancer clinics, after-hours GP services, IT solutions for general practices, and various community-based healthcare programs. Operating internationally, the company has a significant presence in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, and Belgium. Founded in 1934, Sonic Healthcare Limited is headquartered in Sydney, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA,
Target Price
The average target price of SHL.AX is 23 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation